Predictive value of fibrinolytic factors in coronary heart disease

References

• Wiman B. Plasminogen activator inhibitor 1 in thrombotic disease. Current opinion in Hematology 1996; 3: 372–378
   PubMedGoogle Scholar
• Hamsten A, de Faire U, Walldius G, Dahlén G, Szamosi A, Landou C, Blombäck M, Wiman B. Plasminogen activator inhibitor in plasma:risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3–9
   PubMed Web of Science ®Google Scholar
• Cortellaro M, Cofrancesco E, Boscheti C, Mussoni L, Donati M B, Cardillo M, Catalano M, Gabrielli L, Lombardi B, Specchia G, Tavazzi L, Tremoli E, Pozzoli E, Turri M, for the PLAT Group. Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in artherosclerotic patients - a case-control study. Arterioscler Thromb 1993; 13: 1412–1417
   PubMedGoogle Scholar
• Held C, Hjelmdahl P, Rehnqvist N, Wallén H, Björkander I, Eriksson S, Forslund L, Wiman B. Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metoprolol. Circulation 1997; 95: 2380–2386
   PubMed Web of Science ®Google Scholar
• Jansson J H, Nilsson T K, Olofsson B O. Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. Eur Heart J 1991; 12: 157–161
   PubMed Web of Science ®Google Scholar
• Ridker P M, Vaughan P E, Stampfer M J, Manson J E, Hennehens C H. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341: 1165–1168
   PubMed Web of Science ®Google Scholar
• Schulman S, Wiman B. The significance of hypofibrinolysis for the risk of recurrence of venous thromboembolism. Thromb Haemost 1996; 75: 607–611
   PubMed Web of Science ®Google Scholar
• Thompson S G, Kienast J, Pyke S DM, Haverkate F, van de Loo JCW, for the European concerted action on thrombosis and disabilities angina pectoris study group. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med. 1995; 322: 635–641
   Google Scholar
• Nilsson T K. Analysis of factors affecting tissue plasminogen activity and antigen concentration before and after venous occlusion in 123 patients. Clin Chem Enzymol Comm 1989; 1: 335–341
   Google Scholar
• Wiman B, Hamsten A. Impaired fibrinolysis and risk of thromboembolism. Progr Cardiovasc Dis 1991; 34: 179–192
   PubMed Web of Science ®Google Scholar
• Nordenhem A, Wiman B. Tissue plasminogen activator (tPA) antigen in plasma:correlation with different tPA/inhibitor complexes. Scand J Clin Lab Invest 1998; 58: 475–484
   PubMed Web of Science ®Google Scholar
• Wiman B., Collen D. On the Molecular Mechanisms of Physiological Fibrinolysis. Nature 1978; 272: 549–550
   PubMed Web of Science ®Google Scholar
• Chmielewska J, Rånby M, Wiman B. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 1983; 31: 427–436
   PubMed Web of Science ®Google Scholar
• Kruithof E KO, Tran-Thang C, Ransijn A, Bachmann F. Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood 1984; 64: 907–913
   PubMed Web of Science ®Google Scholar
• Chmielewska J, Rånby M, Wiman B. Kinetics of the inhibition of plasminogen activators by the plasminogen-activator inhibitor. Evidence for ‘second-site’ interactions. Biochem J 1988; 251: 327–332
   PubMedGoogle Scholar
• Wiman B, Haegerstrand-Björkman M. Plasmin/2-antiplasmin complex in plasma - a global fibrinolytic assay. Thromb Haemostas 1993; 69: 1091, abstract no 1958
   Google Scholar
• Pedersen O D, Gram J, Jespersen J. Plasminogen activator inhibitor type-1 determines plasmin formation in patients with ischaemic heart disease. Thromb Haemostas 1995; 73: 835–840
   PubMedGoogle Scholar
• Loskutoff D J, van Mourik J A, Erickson L A, Lawrence D. Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells. Proc Natl Acad Sci U S A 1983; 80: 2956–2960
   PubMedGoogle Scholar
• Gelehrter T D, Barouski P. A. Miller, Coleman P L, Cwikel B J. Hormonal regulation of plasminogen activator in rat hepatoma cells. Mol Cell Biochem 1983; 53–54: 11–21
   PubMedGoogle Scholar
• Laug W. Vascular smooth muscle cells inhibit the plasminogen activators secreted by endothelial cells. Thromb Haemostat 1985; 53: 165–169
   PubMedGoogle Scholar
• Kruithof E KO, Tran-Thang C, Bachman F. Studies on the release of a plasminogen activator inhibitor by human platelets. Thromb Haemostat 1986; 55: 201–205
   PubMed Web of Science ®Google Scholar
• Samad F, Yamamoto K, Loskutoff D J. Distribution and regulation of plasminogen activator inhibitor 1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysaccharide. J Clin Invest 1996; 97: 37–46
   PubMed Web of Science ®Google Scholar
• Lundgren C H, Brown S L, Nordt T K, Sobel B E, Fujii S. Elaboration of type-1 plasminogen activator inhibitor from adipocytes. A potential pathogenetic link between obesity and cardiovascular disease. Circulation 1996; 93: 106–110
   PubMed Web of Science ®Google Scholar
• Andreotti F, Davies G J, Hackett D R, Khan M I, de Bart A C, Aber V R, Maseri A, Kluft C. Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardiac death and stroke. Am J Cardiol 1988; 62: 635–637
   PubMed Web of Science ®Google Scholar
• Grimaudo V, Hauert J, Bachmann F, Kruithof E KO. Diurnal variation of the fibrinolytic system. Thromb Haemostas 1988; 59: 495–499
   PubMed Web of Science ®Google Scholar
• Angelton P, Chandler W L, Schmer G. Diurnal variation of tissue-type plasminogen activator and its rapid inhibition. Circulation 1989; 79: 101–106
   PubMedGoogle Scholar
• Dawson S, Hamsten A, Wiman B, Henney A, Humphries S. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arteriosclerosis Thromb 1991; 11: 183–190
   PubMed Web of Science ®Google Scholar
• Dawson S J, Wiman B, Hamsten A, Green F, Humphries S, Henney A M. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993; 268: 10739–10745
   PubMed Web of Science ®Google Scholar
• Loskutoff D J, Linders M, Keijer J, Veerman H, van Heerikhuizen H, Pannekoek H. Structure of the human plasminogen activator inhibitor 1 gene:nonrandom distribution of introns. Biochemistry 1987; 26: 3763–3768
   PubMed Web of Science ®Google Scholar
• Strandberg L, Lawrence D, Ny T. The organization of the human-plasminogen-activator-inhibitor-1 gene. Implications on the evolution of the serine-protease inhibitor family. Eur J Biochem 1988; 176: 609–616
   PubMedGoogle Scholar
• van Hinsbergh V W, Kooistra T, van den Berg E A, Princen H M, Fiers W, Emeis J J. Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivo. Blood 1988; 72: 1467–1473
   PubMed Web of Science ®Google Scholar
• Klinger K W, Winqvist R, Riccio A, Andreasen P A, Sartorio R, Nielsen L S, Stuart N, Stanislovitis P, Watkins P, Douglas R, Grzeschik K H, Alitalo K, Blasi F, Danø K. Plasminogen activator inhibitor type 1 gene is located at region q21.3-q22 of chromosome 7 and genetically linked with cystic fibrosis. Proc Natl Acad Sci U S A 1987; 84: 8548–8552
   PubMed Web of Science ®Google Scholar
• Falk G, Almqvist Å, Nordenhem A, Svensson H, Wiman B. Allele specific PCR for detection of a sequence polymorphism in the promoter region of the plasminogen activator inhibitor-1 (PAI-1) gene. Fibrinolysis 1995; 9: 170–174
   Google Scholar
• Colucci M, Paramo J A, Collen D. Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest 1985; 75: 818–824
   PubMed Web of Science ®Google Scholar
• Emeis J J, Kooistra T. Interleukin-1 and lipopolysaccharide induce a fast-acting inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells. J Experimental Med 1986; 163: 1260–1266
   PubMed Web of Science ®Google Scholar
• Eriksson B, Eriksson E, Gyzander E, Teger-Nilsson A C, Thorsen S, Risberg B. Thrombosis after hip replacement, relationship to the fibrinolytic system. Acta Orthop Scand 1989; 60: 159–163
   PubMed Web of Science ®Google Scholar
• Wallen P, Bergsdorf N, Rånby M. Purìfication and characterization of two structural variants of porcine tissue plasminogen activator by affinity adsorption on fibrin. Biochim Biophys Acta 1982; 719: 318–328
   PubMedGoogle Scholar
• Rånby M. Studies on the kinetics of plasminogen activation by tissue plasminogen activator. Biochim Biophys Acta 1982; 704: 461–469
   PubMedGoogle Scholar
• Biessen E A, van Teijlingen M, Vietsch H, Barrett-Bergshoeff M M, Bijsterbosch M K, Rijken D C, van Berkel T J, Kuiper J. Antagonists of the mannose receptor and the LDL receptor-related protein dramatically delay the clearance of tissue plasminogen activator. Circulation 1997; 95: 46–52
   PubMedGoogle Scholar
• Wiman B, Hamsten A. Impaired fibrinolysis and risk of thromboembolism. Progr Cardiovasc Dis 1991; 34: 179–192
   PubMed Web of Science ®Google Scholar
• Schulman S, Wiman B, for the Duration of Anticoagulation (DURAC) Trial Study Group. The significance of hypofibrinolysis for the risk of recurrence of venous tromboembolism. Thromb Haemostas, in press
   Google Scholar
• Erickson L A, Fici G J, Lund J E, Boyle T P, Polites H G, Marotti K R. Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene. Nature 1990; 346: 74–76
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Schoonjans L, Kieckens L, Ream B, Degen J, Bronson R, De-Vos R, van-den-Oord J J, Collen D, Mulligan R C. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994; 368: 419–24
   PubMed Web of Science ®Google Scholar
• Mellbring G, Dahlgren S, Wiman B. Plasma fibrinolytic activity in patients undergoing major abdominal surgery. Acta Chir Scand 1985; 151: 109–114
   PubMedGoogle Scholar
• Paramo J A, Alfaro M J, Rocha E. Postoperative changes in the plasmatic levels of tissue-type plasminogen activator and its fast-acting inhibitor - Relationship to deep vein thrombosis and influence of prophylaxis. Thromb Haemostas 1985; 54: 713–716
   PubMed Web of Science ®Google Scholar
• Hamsten A, Wiman B, de Faire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557–1563
   PubMed Web of Science ®Google Scholar
• Jansson J H, Olofsson B O, Nilsson T K. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. A 7-year follow-up. Circulation 1993; 88: 2030–2034
   PubMed Web of Science ®Google Scholar
• Reutervall C, Hallqvist J, Ahlbom A, deFaire U, Diderichsen F, Hogstedt C, Pershagen G, Theorell T, Wiman B, Wolk A, and the SHEEP study group. Same risk of myocardial infarctionin men and women? Analysis of some major risk factors in the SHEEP study. J Int Med., In press
   Google Scholar
• Eriksson P, Kallin B, van't Hooft F M, Båvenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A 1995; 92: 1851–1855
   PubMed Web of Science ®Google Scholar
• Ye S, Green F R, Scarabin P Y, Nicaud V, Bara L, Dawson S J, Humphries S E, Evans A, Luc G, Cambou J P, Arveiler D, Henney A M, Cambien F. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Thromb Haemost 1995; 74: 837–841
   PubMed Web of Science ®Google Scholar